secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268935
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine completes EPP trial enrollment; bitopertin shows PPIX reduction and light tolerance gains
--------------------------------------------------------------------------------

- Enrollment complete for Phase 2 BEACON (n=22 adults) and AURORA (n=75 adults) bitopertin trials in EPP; BEACON expanded to adolescents.
- Interim BEACON data: mean PPIX reduction of 39% by Day 43; patients with >30% PPIX reduction averaged >10 hours weekly sunlight tolerance improvement.
- Proportion of prodrome-free sunlight challenges rose from 2% to 49%; phototoxic reactions decreased 93% on bitopertin.
- Initial DISC-0974 data in MF with anemia shows dose-dependent hepcidin reductions and serum iron increases; no serious AEs reported.
- Updated BEACON data and preliminary DISC-0974 results to be presented at ASH Dec 11; conference call same day at 9:30 PM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523268935/0001193125-23-268935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523268935/d569217d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer